13F Pro quality score
Rank #2,876 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
AIM ImmunoTech Inc. (AIM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AIM at 9.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,876 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), AIM ImmunoTech Inc. reports quarterly revenue of $26.0K, net income of $-3.8M. AIM trades on the NYSE exchange and files with the SEC under CIK 946644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AIM ImmunoTech Inc. directly from SEC EDGAR.